Therefore, whether the NVs express fusion protein of PD‐1 and SIRPα high‐affinity consensus (HAC) can integrate all the advantages and have synergistic effects on tumour immunomodulation becomes attractive. The gene discussed is PDCD1; the disease is neoplasm.